These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8221559)

  • 1. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
    Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
    Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP).
    Ardizzoni A; Rosso R; Salvati F; Scagliotti G; Soresi E; Ferrara G; Pennucci C; Baldini E; Cruciani AR; Antilli A
    Am J Clin Oncol; 1991 Apr; 14(2):120-3. PubMed ID: 1851386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer.
    Cartei G; Cartei F; Cantone A; Causarano D; Genco G; Tobaldin A; Interlandi G; Giraldi T
    J Natl Cancer Inst; 1993 May; 85(10):794-800. PubMed ID: 8387607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomized trial.
    Zarogoulidis K; Ziogas E; Papagiannis A; Charitopoulos K; Dimitriadis K; Economides D; Maglaveras N; Vamvalis C
    Lung Cancer; 1996 Sep; 15(2):197-205. PubMed ID: 8882986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study.
    Halme M; Maasilta PK; Pyrhönen SO; Mattson KV
    Eur J Cancer; 1994; 30A(1):11-5. PubMed ID: 8142151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non small cell lung cancer (NSCLC). A prospective randomized trial with alternating chemotherapy CEP/MEC' versus no treatment.
    Cellerino R; Tummarello D; Porfiri E; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
    Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1839-43. PubMed ID: 2851443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
    Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II-III trial of combination beta and gamma interferons and etoposide and cisplatin in inoperable non-small cell cancer of the lung.
    Schiller JH; Storer B; Dreicer R; Rosenquist D; Frontiera M; Carbone PP
    J Natl Cancer Inst; 1989 Nov; 81(22):1739-43. PubMed ID: 2553993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer.
    Cellerino R; Tummarello D; Guidi F; Isidori P; Raspugli M; Biscottini B; Fatati G
    J Clin Oncol; 1991 Aug; 9(8):1453-61. PubMed ID: 1649267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
    Kelly K; Crowley JJ; Bunn PA; Hazuka MB; Beasley K; Upchurch C; Weiss GR; Hicks WJ; Gandara DR; Rivkin S
    J Clin Oncol; 1995 Dec; 13(12):2924-30. PubMed ID: 8523056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force.
    Rosso R; Salvati F; Ardizzoni A; Gallo Curcio C; Rubagotti A; Belli M; Castagneto B; Fusco V; Sassi M; Ferrara G
    Cancer; 1990 Jul; 66(1):130-4. PubMed ID: 2162239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.
    Vokes EE; Haraf DJ; Hoffman PC
    Cancer Chemother Pharmacol; 1993; 33(3):203-9. PubMed ID: 8269601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of cisplatin and interferon-alpha 2a (Roferon-A) in patients with non-small cell lung cancer (NSCLC). An open phase II multicentre study.
    Kataja V; Yap A
    Eur J Cancer; 1995; 31A(1):35-40. PubMed ID: 7695976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
    Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
    J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial.
    Prior C; Oroszy S; Oberaigner W; Schenk E; Kummer F; Aigner K; Hausmaninger H; Peschel C; Huber H
    Eur Respir J; 1997 Feb; 10(2):392-6. PubMed ID: 9042638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group study.
    Hussain M; Benedetti J; Smith RE; Rodriguez GI; Schuller D; Ensley J
    Cancer; 1995 Oct; 76(7):1233-7. PubMed ID: 8630903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.